Synergy "Neurobiogen, New Drug Substance 'KDS2010' Patent Registered in the US and Canada"

[Asia Economy Reporter Hyunseok Yoo] Neurobiogen, invested by bio and medical device specialist Synergy Innovation, announced on the 30th that its new drug development substance KDS2010 has completed patent registration in the United States and Canada.

Following patent registrations in Japan, Australia, Russia, and eight European countries, the patent registration in the major global medical markets of the United States and Canada is evaluated as establishing a foothold for full-scale global expansion. Through the patent registration, Neurobiogen has secured rights for all neurodegenerative diseases, including Alzheimer's dementia, Parkinson's, epilepsy, and depression.

Currently, Neurobiogen is conducting raw material processing for clinical trials and is developing with the goal of early market entry using the fast track through designation as an orphan drug by the U.S. FDA for spinal cord injury.

The company stated, "With this patent registration, we are entering the clinical stage targeting rare diseases and are conducting overseas technology transfers as a global new drug based on differentiated new substances."

Meanwhile, Synergy Innovation invested in Neurobiogen's convertible bonds (CB) in November 2019 to secure a new drug development pipeline and new growth engines. Upon conversion of the CB, it will secure the status of the largest shareholder.

This content was produced with the assistance of AI translation services.